Marinus Pharmaceuticals announces USPTO patent for ganaxolone IV

Marinus Pharmaceuticals “announced that the United States Patent and Trademark Office has granted a new method of use patent for intravenous ganaxolone in the treatment of status epilepticus, expiring in 2040. The USPTO issued U.S. Patent No. 11,679,117, covering the clinical dosing regimen administering ganaxolone for SE patients, including those with refractory and super refractory status epilepticus. This is Marinus’ second method of use patent granted for IV ganaxolone in SE, broadening the dosing regimen and further strengthening the Company’s intellectual property position.”